Advertisement

Topics

Ayala Pharmaceuticals Company Profile

17:59 EDT 21st October 2018 | BioPortfolio

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The company was founded in November 2017 with an experienced global management team and a strong investor base. The management bench recently expanded with the appointment of Andrea Vergara-Silva, M.D. as Chief Medical Officer. Ayala raised $17 million in a series A financing to fund the company’s licensed product asset, Bristol-Myers Squibb BMS-906024 (now AL101), through a Phase 2 trial. The exclusive worldwide license agreement with Bristol-Myers Squibb includes two gamma secretase inhibitors, AL101 (BMS-906024) and AL102 (BMS-986115), which were previously developed by BMS as Notch inhibitors for oncology indications.


News Articles [373 Associated News Articles listed on BioPortfolio]

Ayala Pharmaceuticals gets $17mm in Series A round

Ayala Pharmaceuticals (Israeli start-up developing cancer therapies) raised $17mm through its Series A round. Company investors include Israel Biotech Fund, aMoon, and Harel Insurance.

Francisco J. Ayala, Famed Biologist, Resigns After Sexual Harassment Inquiry

Administrators at the University of California, Irvine, said they would remove Dr. Ayala’s name from campus buildings and academic posts.

Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

Ayala Pharma, which launched in late 2017, has raised $17m via a series A financing round to propel its lead...    

Cancer drug developer Ayala Pharmaceuticals raises $17m

The funds will take the Israeli company through initial results in the first Phase II study in recurrence or metastatic Adnoid Cystic Carcinoma.

Ayala reports Phase Ib data for AL101 in solid tumors

California Credit Union Awards 10 Scholarships to Los Angeles County Students

Stacy Aka, University High School, Los Angeles Zheng Ni Dong, Ruben S. Ayala High School, Chino Hills Anthony Ho, Francisco Bravo Read more...

FDA Tells RegeneRx It Needs 3rd Phase III Trial On RGN-259 For Dry Eye Syndrome

The FDA is requiring an additional RGN-259 Phase III trial to further show efficacy in both signs and symptoms of...   

Continuing Dismay In Alzheimer's: vTv's RAGE Antagonist Fails In Phase III Study

A further mechanism of action has proven ineffective in top-line data from a late-stage study in Alzheimer's disease, adding to...   

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [141 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

Clinical Trials [225 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1331 Associated Companies listed on BioPortfolio]

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The compa...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

Avanir Pharmaceuticals

AVANIR Pharmaceuticals, formerly LIDAK Pharmaceuticals, is a development stage company organized to discover, develop, and market novel therapeutic products to treat human diseases.

More Information about "Ayala Pharmaceuticals" on BioPortfolio

We have published hundreds of Ayala Pharmaceuticals news stories on BioPortfolio along with dozens of Ayala Pharmaceuticals Clinical Trials and PubMed Articles about Ayala Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ayala Pharmaceuticals Companies in our database. You can also find out about relevant Ayala Pharmaceuticals Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record